You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
06. Ovarian cancer
#170 Long-term survival benefit of radical surgery for treatment patients with advanced epithelial ovarian cancer
Free
  1. Jesús Molero Vílchez1,2,
  2. Ester Martínez Lamela3,4,
  3. Angela Santiago Gómez5,
  4. Anabel Antonio Da Conceicao6,
  5. Sonsoles Sancho García7,
  6. Yolanda Expósito Lucena8 and
  7. Marta Heras García3
  1. 1Toco-Gyn Gynecological Clinic, Alcalá De Henares, Spain
  2. 2Ntra Sra del Rosario University hospital, Madrid, Spain
  3. 3Ntra Sra del Rosario University Hospital, Madrid, Spain
  4. 4Infanta Leonor University Hospital, Madrid, Spain
  5. 5Advance Tecniques Cancer Center (ITACC), Madrid, Spain
  6. 6Jiménez Ayala Institute, Madrid, Spain
  7. 7Ramón y Cajal University Hospital, Madrid, Spain
  8. 8Toco-Gyn Gynecologic Clinic, Alcalá De Henares, Spain

Abstract

Introduction/Background The aim of this study was to evaluate the long-term survival benefit of radical surgery for advanced epithelial ovarian, tubal, and primary peritoneal cancers (stages III-IV FIGO 2017) who had primary cytoreductive surgery (PDS), those that received neoadjuvant platinum-based chemotherapy (NAC) followed by interval debulking surgery (IDS) and those that received only chemotherapy (ChT).

Methodology Observational, longitudinal, analytical, and retrospective study of 101 women between January 2008-March 2023. Association between clinical, imaging, serum markers, surgical and pathological characteristics, and disease recurrence and overall survival was examined in univariable and multivariable analysis (Kaplan-Meier and Cox proportional hazard model).

Results With an overall mean follow-up of 42 months. 47 women (PDS), 28 (IDS) and 26 (ChT) women were included.

Rates of complete resection (R0) were 72.3% of patients after PDS and 57.2% of patients after IDS (p=0.217). Postoperative rates of adverse effects and mortality were slightly higher after PDS than after IDS (p=0.793). Median progression-free survival was 60 months in the PDS group and 52 months in the IDS group (p=0.04). Factors in multivariable analysis associated with increased risk of recurrence included residual tumor >1cm (HR: 2.72, 95% CI 1.06–6.98, p= 0.037) and stable/progression in response to chemotherapy (HR 8.85, 95% CI 1.76–44.45, p= 0.008).

Median overall survival was not reached for the PDS group and 78 months for the IDS group (HR: 1.63, 95% CI 0.72–3.65, p= 0.235) and 28 months for the ChT group (HR: 2.47, 95% CI 1.13–5.39, p=0.022).

Conclusion PDS before chemotherapy is the standard of care. Higher complete cytoreduction rate in the PDS group indicates that the correct patients have been selected and those that benefit the most.

Abstract #170 Figure 1
Abstract #170 Figure 1

Primary vs Interval Debulking Surgery in advanced ovarian cancer

Disclosures Complete resection of all macroscopic disease (at primary or interval surgery) was the strongest independent variable in predicting overall survival (HR: 4.52, 95% CI 1.86–11.02, p= 0.001).

http://dx.doi.org/10.1136/ijgc-2023-ESGO.529

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.